BiotechTube

STRO-002 + Bevacizumab

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer

Conditions

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

Trial Timeline

Mar 22, 2022 → Jun 1, 2025

NCT ID
NCT05200364

About STRO-002 + Bevacizumab

STRO-002 + Bevacizumab is a phase 1 stage product being developed by Sutro Biopharma for Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05200364. Target conditions include Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer.

What happened to similar drugs?

11 of 20 similar drugs in Ovarian Cancer were approved

Approved (11) Terminated (4) Active (7)
✅OlaparibAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved
✅Ganirelix acetateMerckApproved
✅Triptorelin 0.2 mgMerckApproved
✅Pegylated Liposomal Doxorubicin hydrochlorideMerckApproved
✅fosaprepitant + aprepitantMerckApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05200364Phase 1Terminated

Competing Products

20 competing products in Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
azenosertibZentalis PharmaceuticalsPhase 2
32
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
22
pemetrexed + topotecanEli LillyPhase 1
29
arzoxifene hydrochlorideEli LillyPhase 2
35
LY4337713Eli LillyPhase 1
36
PrexasertibEli LillyPhase 2
35
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
32
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
27
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
42
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
47
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
35
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
32
Enzalutamide 40 MGAstellas PharmaPhase 2
35
ASP0739Astellas PharmaPhase 1/2
24
IMAB027Astellas PharmaPhase 1
29